|
gptkbp:instanceOf
|
gptkb:drug
stimulant
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
A08AA01
|
|
gptkbp:brand
|
Adipex-P
Lomaira
Suprenza
|
|
gptkbp:broadcastOn
|
Schedule IV (US)
|
|
gptkbp:CASNumber
|
122-09-8
|
|
gptkbp:chemicalFormula
|
phenethylamine derivative
|
|
gptkbp:contraindication
|
gptkb:cardiovascular_disease
pregnancy
glaucoma
hyperthyroidism
|
|
gptkbp:discontinued
|
gptkb:United_Kingdom
|
|
gptkbp:discoveredIn
|
1950s
|
|
gptkbp:drugClass
|
sympathomimetic amine
|
|
gptkbp:eliminationHalfLife
|
19-24 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C10H15N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
phentermine
|
|
gptkbp:interactsWith
|
gptkb:monoamine_oxidase_inhibitors
other stimulants
|
|
gptkbp:IUPACName
|
2-methyl-1-phenylpropan-2-amine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:South_Africa
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
appetite suppressant
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notRecommendedFor
|
long-term use
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:relatedTo
|
amphetamine
|
|
gptkbp:riskFactor
|
abuse
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
increased heart rate
insomnia
elevated blood pressure
dry mouth
|
|
gptkbp:soldIn
|
gptkb:European_Union
|
|
gptkbp:synonym
|
α,α-dimethylphenethylamine
|
|
gptkbp:usedFor
|
weight loss
|
|
gptkbp:bfsParent
|
gptkb:sitagliptin
|
|
gptkbp:bfsLayer
|
6
|